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Abstract
Background: Current health policies assume that prescribing is more efficient and rational when
general practitioners (GPs) work with a formulary or restricted drugs lists and thus with a limited
range of drugs. Therefore we studied determinants of the range of drugs prescribed by general
practitioners, distinguishing general GP-characteristics, characteristics of the practice setting,
characteristics of the patient population and information sources used by GPs.
Methods: Secondary analysis was carried out on data from the Second Dutch Survey in General
Practice. Data were available for 138 GPs working in 93 practices.
ATC-coded prescription data from electronic medical records, census data and data from GP/
practice questionnaires were analyzed with multilevel techniques.
Results: The average GP writes prescriptions for 233 different drugs, i.e. 30% of the available drugs
on the market within one year. There is considerable variation between ATC main groups and
subgroups and between GPs. GPs with larger patient lists, GPs with higher prescribing volumes and
GPs who frequently receive representatives from the pharmaceutical industry have a broader range
when controlled for other variables.
Conclusion: The range of drugs prescribed is a useful instrument for analysing GPs' prescribing
behaviour. It shows both variation between GPs and between therapeutic groups. Statistically
significant relationships found were in line with the hypotheses formulated, like the one concerning
the influence of the industry. Further research should be done into the relationship between the
range and quality of prescribing and the reasons why some GPs prescribe a greater number of
different drugs than others.
Background
Prescribing a drug is one of the most frequent therapeuti-
cal decisions by general practitioners (GPs). There are
numerous different drugs on the market, which means
that GPs usually have a choice of several different drugs
even when treating the same health problem. The aggre-
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gated costs for prescription drugs are high and increasing,
however, and several policy initiatives have therefore been
implemented against the background of this spiralling
expense. One such initiative is to restrict GP prescribing to
drugs that are on an indicative drug list, which was intro-
duced in the UK.
In the absence of an indicative drug list in the Nether-
lands, it is important to know what influences the range
that GPs prescribe. In the Netherlands, 75 percent of all
drugs are prescribed by GPs and 65% of consultations end
with a prescription [1]. Moreover, drug costs are rising
sharply and they constitute an important expense in
health care [2]. Current health policies assume that pre-
scribing is more efficient and rational when GPs work
with formulary or restricted drugs lists and thus with a
limited range of drugs [3,4]. An advantage of using a lim-
ited range of drugs is that GPs become more familiar with
drug dosages, contra-indications, interactions, etc., result-
ing in a lower incidence of side effects and dangerous
interactions [5,6]. Especially, the number of analogue
drugs (drugs consisting of various chemical substances,
but used for the same condition) should be limited [6].
This should translate into lower costs [7].
There have been previous studies of the prescribing pat-
terns of GPs, but most studies focused on differences in
the total amount of prescriptions or on prescriptions for a
particular group of drugs [8-10]. Little is known to date
about the variation in the numbers of different drugs (the
range) that GPs prescribe and about the factors that might
explain these variations between GPs. Two studies
showed that the number of doctors in the practice is pos-
itively related to the range of drugs prescribed [6,11]. The
last study also found higher ranges in practices with high
patient lists per doctor, a high percentage of elderly and a
heavy workload. One study found no consistent relation-
ship between the adoption of new drugs and previous pre-
scribing of drugs belonging to the same therapeutic class
[12]. Taylor e.a. linked GP characteristics (including their
information sources) to prescribing in terms of adding
new drugs to their repertory [13]. Another study showed
that for two out of six therapeutic groups there was a pos-
itive association between number of years in practice and
range of drugs [14].
The purpose of this study is to determine whether there is
variation between GPs in the range of drugs they prescribe
and whether there is variation within therapeutic groups
of drugs, and how these differences can be explained. Our
analysis is at the level of GPs where most recent studies
were at practice level. Secondly, more determinants were
taken into consideration, especially with respect to the
GPs' information sources and the influence of patient
characteristics.
Hypotheses
It can be expected that known determinants of rational
prescribing are also relevant in explaining the variation in
the range of drugs prescribed. These determinants partly
relate to individual GPs' prescribing decisions [15,16].
Differences in the range of drugs prescribed will also
depend on individual GP characteristics, the practice set-
ting in which he works and the composition of the prac-
tice population [17]. Further the way GPs acquire
knowledge about new drugs might play a role [18].
First, individual characteristics of GPs might influence the
range. Gender of the GP is not assumed to be directly
related to the range of drugs prescribed. The age of the GP
might have an influence in so far as age indicates years of
experience. The direction of the relationship is difficult to
hypothesize beforehand, however, because age (more
experience) might be related to a smaller range of drugs
(as a consequence of less uncertainty) or to a broader
range (as a consequence of less up-to-date knowledge on
pharmacotherapy). The individual list size might be posi-
tively related to the range of drugs simply because a higher
number of patients increases the chance on a wider range
of drugs. Further we can assume that GPs that are more
inclined to prescribe in general might also be inclined to
prescribe more different drugs.
Second, the practice setting in which the GP works might
be of influence. Previous research showed that the
number of doctors in the practice was positively related to
the range at practice level [6,11], which could be
explained by the fact that the combined repertory of more
doctors will generally be larger than those of individual
doctors. This does not mean, however, that individual
GPs within group practices have larger ranges, although
the fact that patients tend to switch between GPs in a
group practice might influence the range positively. Dis-
pensing practices might have a smaller range of drugs (as
a consequence of more pharmaco-therapeutic knowledge,
or for simple economic reasons of wanting to restrict the
number of drugs in stock), but data for dispensing prac-
tices might also contain drugs that were prescribed by hos-
pital consultants, which would result in a broader range.
Third, the practice population might influence the range of
drugs prescribed. In general a more complex practice pop-
ulation is hypothesized to be related to a broader range of
drugs prescribed, as a consequence of greater use of health
services, worse health and more diverse health problems
of urban residents, especially where mental health is con-
cerned. So we expect a broader range in urban areas, espe-
cially in deprived areas, in practices with a high percentage
of elderly and patients from non-western origin
[16,19,20]. More people with higher education and fewer
publicly insured people in a practice might be related to aBMC Health Services Research 2007, 7:132 http://www.biomedcentral.com/1472-6963/7/132
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broader range (the higher educated may be more
demanding and new drugs are not always reimbursable
for publicly insured patients).
Finally the GPs' pharmaceutical information sources espe-
cially on new drugs might play a role. In general it can be
assumed that GPs who use independent sources of infor-
mation will prescribe a smaller range of drugs, because
independent sources will stress the 'me too' character of
many new drugs[3,9,15,21]. Collaboration between GP
and pharmacist can lead to more restricted formulary
based prescribing [22,23]. Reliance on the pharmaceutical
industry as a source of information is assumed to be
related to a broader range of drugs prescribed, because
these sources will stress the advantages of new drugs
[3,9,21,24-26].
Methods
Data were analyzed from the Second Dutch National Sur-
vey of General Practice, a large scale study held in 2001.
Data were collected in 104 computerized general practices
with 195 GPs serving a population of approximately
400,000 residents. The data include background informa-
tion on the patients involved, collected from the practice
computer (list size, insurance type) and via a census (e.g.
education, ethnicity, occupation), approximately 14,000
health interview surveys, and 1.4 million electronically
coded medical records (consultations, diagnosis, prescrip-
tions, referrals) kept of all patients contacting the GP in
2000/1 [27]. Further information on GP and practice
characteristics were collected with GP/practice question-
naires. The GP questionnaire included factors affecting GP
prescribing behaviour. The Second Dutch National Survey
of General Practice was carried out according to Dutch leg-
islation on privacy. The privacy regulation of the study
was approved by the Dutch Data Protection Authority.
Prescription data that could be traced to individual GPs
were selected from the electronic medical records. Only
GPs with more than 500 prescribed medications were
included. This resulted in data for 138 GPs working in 93
practices.
Ninety-two percent of all medication prescribed was clas-
sified by active substance according to the Anatomical
Therapeutical Chemical (ATC) classification code devel-
oped by the World Health Organisation (WHO) [28].
Measurement of the range (dependent variable)
We define the range as the number of different drugs pre-
scribed within a certain ATC-system main group (ATC 3)
(Table 1), thereby focusing on the number of analogue
drugs [6]. Not all the therapeutic groups within the ATC-
system were relevant for this study. Some therapeutic
groups were excluded for reasons that included the fol-
lowing:
- they offered too little drug choice; only a few drugs are
available within these groups (e.g. N07: other CNS drugs,
including parasympathomimetics)
- they concerned an unusual disorder which has a very low
prevalence (e.g. H: systemic hormonal preparations
excluding sex hormones)
- they concerned diseases which are treated only by spe-
cialists and not by GPs (e.g. L: antineoplastic and immu-
nosuppressive drugs)
On the other hand, there were some important subgroups
(ATC-4) for which it would be favourable to determine
the range for these groups separately, e.g. the anti-psy-
chotics (N05A), the anti-depressants (N06A), etc.
ATC codes were recorded at GP level. The explanatory
analysis used an overall score for the range, instead of sep-
arate range values for the different therapeutic groups.
This score was computed by summing the ranges over the
ATC3/ATC4 subgroups (see total in table 1). Factor analy-
sis showed that the scores for the various subgroups were
unidimensional.
Measurement of the explanatory variables
The following explanatory variables were included in the
analysis. Unless otherwise indicated, these were derived
from the GP/practice questionnaires.
GP background characteristics
- Age and gender of the GP.
- Individual list size (practice computer).
Practice characteristics
- Type of practice (single-handed, duo, group; entered as
dummy variables in the analysis),
- dispensing practice,
- number of prescriptions per listed patient per year (elec-
tronic medical records/practice computer): we hypothe-
sized a relationship at GP-level. Because of data problems
we had to include this variable at practice level, however.
Practice population characteristics
- Degree of urbanization (as classified by Statistics Nether-
lands on a five-point scale ranging from not urbanized to
very strongly urbanized; entered as dummy variables in
the analysis),BMC Health Services Research 2007, 7:132 http://www.biomedcentral.com/1472-6963/7/132
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Table 1: Mean and variation between GPs in range of the selected therapeutical main or subgroups*
ATC Average range Coefficient of 
variation
Min Max Number of 
drugs on 
the market
Range as % of 
drugs on the 
market
Antacids, drugs for treatment of peptic ulcers/flatulence A02 10.90 28.85 3 20 32 34.1
Laxatives A06 7.41 32.60 2 13 24 30.9
Drugs used in diabetes A10 8.80 26.02 3 14 17 51.8
Insulins A10A 3.78 38.15 1 7 7 54.0
Oral blood glucose lowering drug A10B 5.12 22.56 2 7 10 51.2
Antithrombotic agents B01 5.95 26.27 1 10 27 22.0
Cardiac therapy C01 6.06 26.06 1 10 32 18.9
Diuretics C03 7.04 20.04 3 9 15 46.9
Beta blocking agents C07 8.31 26.56 4 15 26 32.0
Agents acting on the renin-angiotensin system C09 12.09 31.30 3 22 31 39.0
Antifungals for dermatological use D01 6.89 26.69 2 12 17 40.5
Corticosteriods, dermatological preparations D07 12.43 25.40 5 22 27 46.0
Sex hormones and modulators of the genital system G03 21.70 24.78 9 36 56 38.8
Hormonal contraceptives for systemic use G03A 9.30 22.71 4 14 17 54.7
Estrogens G03C 2.89 24.98 1 5 6 48.2
Rest of G03 (G03REST) 9.51 37.70 2 19 33 28.8
Antibacterials for systemic use J01 17.18 15.98 10 24 79 21.7
Anti-inflammatory and antirheumatic products M01 9.02 26.04 4 17 25 36.1
Anti-inflammatory/-rheumatic products. non-steriods M01A 8.92 25.53 4 17 22 40.5
Analgesics N02 12.62 23.49 4 21 40 31.6
Opioids N02A 4.33 28.91 1 7 17 25.5
Other analgesics and antipyretics N02B 3.80 23.55 1 6 13 29.2
Antimigraine preparations N02C 4.48 38.55 1 9 10 44.8
Psycholeptics N05 21.70 27.61 6 37 76 28.6
Antipsychotics N05A 7.85 45.58 1 22 31 25.3
Anxiolytics N05B 7.19 27.84 2 12 16 44.9
Hypnotics and sedatives N05C 6.83 25.36 2 11 29 23.6
Psychoanaleptics N06 12.48 24.26 4 19 33 37.8
Antidepressants N06A 11.24 23.32 4 17 24 46.8
Nasal preparations R01 7.92 24.17 3 12 17 46.6
Anti-asthmatics R03 12.86 20.55 6 20 26 49.5
Cough and cold preparations R05 4.34 36.89 1 9 22 19.7
Antihistamines for systemic use R06 10.20 27.96 3 17 25 40.8
Ophthalmologicals S01 16.98 41.17 5 39 79 21.5
Overall Range 232.87 20.61 111 353 755 30.8
*compared to the number of drugs on the market in 2001.BMC Health Services Research 2007, 7:132 http://www.biomedcentral.com/1472-6963/7/132
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- practice located in deprived urban area (as classified for
additional remuneration of GPs [27]),
- % of practice population older than 75 years (practice
computer),
- % of practice population with higher education, accord-
ing to definition Statistics Netherlands (census),
- % of practice population publicly insured (practice com-
puter),
- % of practice population of non-western origin accord-
ing to definition (census).
GPs' pharmaceutical information sources
- Participation in postgraduate courses (hours per year),
- participation in Pharmaco-therapeutic Audit Meetings
(frequency per year),
- number of different written sources (max. 4) used for
information on new drugs,
- number of different oral sources (max. 3) used for infor-
mation on new drugs,
- number of representatives of pharmaceutical industry
received in the last four weeks,
- mean frequency of use of independent information
sources like guidelines and formularies (4 item five-point
scale ranging from never to often, α = .64),
- mean frequency of use of information sources in the
pharmaceutical industry (on a five-point scale ranging
from never to often, α = .65).
The scales on frequency of use of independent informa-
tion and information from industry appeared to be inde-
pendent factors in a factor analysis with all information
items [21].
Analysis
Descriptive information is given for the range per ATC
group. The coefficient of variation (equal to (standard
deviation/mean)*100) is given instead of the standard
deviation because this enables comparison between ATC-
groups. Bivariate (Pearson) correlation coefficients were
computed between the explanatory variables and with the
overall range. Multiple regression analysis was used to
examine the joint relationship between the dependent
variable and the explanatory variables. Hypotheses were
tested one-tailed with a significance of p < 0.05, where we
had a directional hypotheses and two-tailed when there
was no directional hypotheses. The regression analysis
was performed using multilevel analysis [30,31], due to
the dependence of the observations for GPs working in
the same practice.
Results
Table 1 shows the ranges for the therapeutic main groups
and subgroups selected. The range is of course dependent
on the number of drugs on the market and the number of
drugs on the market was therefore placed as a reference
category, while the range was also computed as a percent-
age of the number of drugs on the market. We see clear
variation between different therapeutic groups in the per-
centages of available drugs used. In the case of cardiac
therapy (C01), antibacterials (J01), antithrombotic agents
(B01) and hypnotics and sedatives (N05C), the average
GP uses less than 25% of the available drugs on the mar-
ket. In contrast, more than 50% of all available insulins
(A10A), hormonal contraceptives (G03A), drugs used in
diabetes (A10) and oral blood glucose lowering drugs
(A10B) are used by the average GP. If we look at all thera-
peutic main groups together, the average GP uses 233 dif-
ferent drugs or 31% of the drugs available on the market.
The second type of variation we can perceive in the table
is between GPs. The total number of drugs prescribed var-
ies between 111 and 353, or between 15% and 47% of the
available drugs on the market. There are differences
between therapeutic main groups and subgroups in this
respect, the coefficient of variation ranging from 16 for
antibacterials to 46 for antipsychotics. The fact that for
both these drug groups the range as a percentage of avail-
able drugs used was low shows that a low range as a per-
centage of available drugs used does not imply
automatically little variation between GPs.
Descriptive information of the explanatory variables used
has been given in table 2, which also shows the relation-
ship of these variables with the overall range. The range is
statistically significantly larger in non-urbanized areas, in
dispensing practices, for GPs with larger patient lists, in
practices with more patients with higher education, in
practices that frequently received representatives of the
pharmaceutical industry and more frequently used infor-
mation sources of the industry, and in practices with a
high prescription volume per patient. We see a statistically
significant smaller range for GPs working in deprived
urban areas. Table 3 shows the statistically significant cor-
relation coefficients between the explanatory variables.
The correlations are moderate at most, which means that
they can be entered together in a multivariate analysis.
The results of the multilevel analysis are shown in table 4.
In the empty model (without explanatory variables), we
found that the amount of variation at GP-level differedBMC Health Services Research 2007, 7:132 http://www.biomedcentral.com/1472-6963/7/132
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significantly from zero. There was no significant variation
at practice level.
The clustering of GPs within practices – the intraclass cor-
relation – is relatively strong, which means that the ranges
for GPs in the same practices are correlated (0.312 in the
full model). Table 4 shows that the prescribing volume at
practice level was significantly and positively related to
the overall range, which also applied at GP level to the
individual list size and the frequency of visits of represent-
atives of the pharmaceutical industry at practice level. All
of this confirms our hypotheses.
Other hypotheses were not confirmed. We did not find
that urban location is related to a broader range, nor did
we find wider ranges in group practices, in practices with
a high proportion of elderly patients, a high proportion of
people with higher education or a low proportion of pub-
licly insured people. In the field of pharmaceutical knowl-
edge, we did not find significant relationships with access
to independent information sources or participation in
Pharmaco-Therapeutic Audit Meetings. Multiple regres-
sion analysis showed that 38% of the total variance could
be explained by the variables used.
Discussion
In this article, we analyzed the concept of the range of
drugs prescribed as an alternative or supplement to more
usual measurements like the total number of prescrip-
tions. The material in this article shows this to be a useful
addition, especially when more precise clinical indicators
are absent. Firstly because the range shows clear variations
between ATC main groups and subgroups, and between
GPs; secondly because it was possible to explain the vari-
ation between GPs by factors that have a theoretically
interpretable relationship to the range. GPs with larger
patient lists, GPs with higher prescribing volumes and
GPs who frequently receive representatives from the phar-
maceutical industry turned out to have a broader range
when controlled for other variables. These statistical rela-
tionships could be linked to the hypotheses we formu-
lated on the basis of the literature or theoretical
considerations.
A measure which is comparable to the range is DU90%
(the number of drugs constituting 90% of the volume
expressed in DDDs). This has been used for GP data in
Stockholm, Sweden, as a general quality indicator in feed-
back [32,33]. In an intervention project aimed at decreas-
ing the number of inhabitants per GP, no systematic
change in DU90% could be detected [33].
For measures of prescribing variation, ideally, guideline
recommendations should be taken into account. Bergman
e.a. [32] did not find a relationship between DU90% and
adherence to a local formulary. The theoretical link
between the range of drugs prescribed and quality of drug
prescribing is based on the use of restrictive formularies or
guidelines. This link was not studied in our article. It
would require specific information on the indication to
prescribe and on the link between indications and guide-
lines or formularies. However, in the absence of detailed
information on indications, the range of drugs could be
used as an overall measure in addition to other drug-spe-
cific measures [34].
The relationship of the range of drugs prescribed with the
number of prescriptions per patient and list size can be
Table 2: Independent variables: descriptive characteristics and 
bivariate correlations with overall range, tested one-tailed*
mean/% Sd corr. with 
range
Age GP (mean/sd)a 47.7 6.1 0.05
Gender GP (% female)a 20 -0.09
Type of practice
Single-handed (%) 35 0.07
duo practice (%) 25 0.13
Group practice (%) 40 -0.04
Degree of urbanisation
very strong (%) 17 -0.15
Strong (%) 23 0.00
moderate (%) 18 -0.04
little (%) 30 0.01
not (%) 12 0.20*
Deprived urban area (%) 9 -0.17*
Dispensing practice (%)** 10 0.25*
Individual list size (mean/sd) 2193 560 0.26*
% patients > 75 yrs (mean/sd) 6.1 2.8 0.07
% patients with higher education 
(mean/sd)
23.1 11.5 0.22*
% patients publicly insured (mean/sd) 66.9 8.7 0.12
% patients of non-western origin 
(mean/sd)
6.5 11.8 -0.01
Hours per year postgraduate 
courses (mean/sd)
55.4 62.2 -0.05
Participation per year in pharm. 
meetings (mean/sd)
7.5 4.1 0.00
Use written information sources 
(mean/sd)
2.1 1.2 0.13
Use oral information sources (mean/
sd)
1.7 1.1 -0.10
Visits (last 4 weeks) representatives 
pharm. ind. (mean/sd)
2 2.9 0.18*
Use independent information 
sources (mean/sd)
3.9 0.8 -0.10
Use information sources industry 
(mean/sd)
1.4 0.6 0.15*
Prescriptions per patient per year 
(mean/sd)
6.5 11.8 0.38*
* p < 0.05.
** Where there was no directional hypothesis two-tailed testing was 
appliedB
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Table 3: Pearson correlation coefficients between explanatory variables (only significant correlations. p < 0.05)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1a g e  G P
2 female GP -0.31
3 single handed -0.17
4 duo practice -0.42
5 group practice 0.27 -0.60 -0.47
6 very strong urban 0.24 -0.17
7 strong urban -0.25
8 moderate urban -0.21 -0.26
9 little urban -0.28 0.31 -0.29 -0.36 -0.31
10 not urban -0.20 -0.17 -0.24
11 deprived urban area 0.28 0.59 -0.21
12 dispensing -0.19 0.40
13 individual list size -0.37 0.36 -0.37 0.25 -0.26
14 % > 75 yrs -0.24 -0.27 -0.18
15 % higher education 0.36 0.20 -0.24 -0.21 0.54 -0.19
16 % sick fund insured -0.60
17 % non-western 0.20 0.26 -0.18 0.52 -0.23 0.36 0.45
18 postgraduate courses 0.17 0.19
19 part. pharm. meetings
20 written info sources -0.17 0.17
21 oral info sources -0.17 0.21 0.20 -0.24
22 visits repres. ind. -0.21 0.39 -0.34 0.35 -0.28 0.38 0.31
23 use indep. sources 0.24 -0.20 0.19 -0.29
24 use sources ind. 0.22 0.29 0.41
25 prescriptions per patient -0.18 0.55 0.43 -0.18 0.29 -0.35 0.24BMC Health Services Research 2007, 7:132 http://www.biomedcentral.com/1472-6963/7/132
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easily understood by the fact that the chance that a greater
number of different drugs will be prescribed is higher
when the number of prescriptions is higher. A second
explanation concerns the role of specialist initiated pre-
scription that is subsequently followed by repeat prescrip-
tions by GPs, a well known phenomenon in the
Netherlands. This might vary between GPs because GPs
who prescribe more usually also refer more to hospital
consultants [35]. Therefore high prescribing GPs might
also prescribe more repeat prescriptions initiated by spe-
cialists, that often deviate from (GP-)guidelines. An addi-
tional explanation for the relationship with prescriptions
per patient may be that a broader drug repertory increases
the inclination to prescribe because it increases the thera-
peutic possibilities of the doctor. The causal direction is
difficult to infer from cross-sectional data as used by us.
This is, of course, a limitation of this study.
A further limitation of our research is that the possibility
of multicollinearity cannot completely be ruled out.
Although the correlations between the independent varia-
bles are below the threshold level of .60 the correlations
with non-urbanized areas (.55) and dispensing practice
(.43) come close to the threshold. In dispensing practices
prescriptions of GPs dispensed by the practice cannot be
separated from specialist prescriptions. Removing the 14
dispensing GPs from the analysis lowered the coefficients
a bit but did not change our overall conclusion.
GPs working in partnerships did not appear to have a
broader range when controlled for other variables. This
seems surprising, because we know from previous
research that GPs in group practices have a broader range.
We expected to see this also on individual level since their
patients more often switch between GPs in group prac-
tices. Table 3 shows that GPs in group practice more often
use oral information sources and receive fewer represent-
atives of the pharmaceutical industry. On the other hand,
working in a group practice is often associated with a
stronger orientation to esteem by colleagues and to pro-
fessional guidelines, leading to more rational prescription
behaviour and therefore to a lower range[36,37]. The
more frequent use of oral information (which will often
be from colleagues) may point to this (see table 3). This
might neutralize the range-broadening effects of patients
switching between doctors.
Contrary to our expectations, we did not find any statisti-
cal relationship with factors associated with the composi-
tion of the practice or with the closely linked factor of the
location of the practice. These were, in fact, proxy-indica-
tors for differences in morbidity. This brings us to the sec-
ond limitation of the study, which is that we did not take
the diagnosis underlying the prescriptions into account.
As a follow-up to this study, we recommend an analysis of
the relationship between range and rational prescribing,
taking diagnosis and comorbidity into account. This
would also provide better opportunities to link the range
of drugs prescribed to guidelines. A more specific follow-
up study would be to investigate how computerized deci-
sion support systems affect the range of drugs prescribed.
Further and more detailed research is necessary into the
differences between therapeutic main groups and sub-
groups with regard to the percentages of available drugs
prescribed. We would hypothesize that GPs have a greater
inclination to switch to other drugs in therapeutic groups
where side-effects play an important role (i.e. hormonal
contraceptives). The same could be true of therapeutic
drugs with limited or variable effectiveness (i.e. antifun-
gals for dermatological use). This is the grey area where
representatives of the pharmaceutical industry play a role,
Table 4: Multilevel regression analysis of the explanatory variables on the overall range of different medicines prescribed by GPs in 
2001
Empty model Full model
Estimate (standard error) Estimate (standard error) Hypothesis
practice level fixed effects
- prescriptions per patient 0.2583 (0.1005)* Confirmed
GP level fixed effects:
- visits representatives industry 0.9289 (0.0456)* Confirmed
- individual list size 0.0000765(0.0002074)* Confirmed
variance components:
practice level intercept 0.1276(0.1521) 0.2684(0.1424)
GP level intercept 0.8419(0.1749)* 0.5914(0.1324)*
intraclass correlation 13.2% 31.2%
*p < 0. 05, one-tailed; N(practices) = 93; n(GPs) = 138.BMC Health Services Research 2007, 7:132 http://www.biomedcentral.com/1472-6963/7/132
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stressing the advantages of their products compared to
other products, in the form of fewer side-effects and better
results.
Conclusion
We conclude that the range of drugs prescribed is a useful
concept that could be used in addition to prescribing vol-
ume in research into prescription behaviour, especially
when information concerning the indication is lacking.
Restriction of the range of drugs as a policy instrument
needs more thorough underpinning by means of further
analysis of both quality and cost correlates of a smaller
range of drugs prescribed.
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